Melinta Therapeutics reports that there will be nine presentations on Melinta programs at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), which is being held April 22-25, 2017 in Vienna, Austria.

The presentations include six posters and e-posters describing the clinical experience with Baxdela™ (delafloxacin), an investigational anionic fluoroquinolone, including important insights into the treatment of challenging patient types such as those who have diabetes, renal impairment, or obesity. ​